Zhaoke Ophthalmology Limited (SEHK: 6622) Company Overview: Founded in 2017, Zhaoke Ophthalmology Limited is a leading ophthalmic pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of therapies that address significant unmet medical needs in the field of ophthalmology. Headquartered in Guangzhou, China, Zhaoke Ophthalmology is committed to improving visual health through innovative scientific research and cutting-edge technology. Mission: Our mission is to enhance the quality of life for patients by providing advanced and effective treatments for eye diseases. We strive to become a global leader in ophthalmology by delivering high-quality, accessible, and affordable eye care solutions. Research and Development: Zhaoke Ophthalmology boasts a comprehensive drug pipeline with 26 candidates targeting major ocular indications affecting both the front and back of the eye. Our R&D efforts are focused on developing innovative therapies for conditions such as dry eye disease, glaucoma, age-related macular degeneration, diabetic retinopathy, and other retinal diseases. We leverage both in-house development and strategic in-licensing to build a robust portfolio of ophthalmic treatments. Manufacturing Capabilities: Our state-of-the-art manufacturing facility in Nansha, Guangzhou, is equipped with advanced technology and adheres to the highest standards of quality and compliance. This facility enables us to efficiently produce both innovative and generic ophthalmic drugs, ensuring a reliable supply of high-quality products to meet the growing demand. Strategic Partnerships: Zhaoke Ophthalmology actively collaborates with leading domestic and international pharmaceutical companies to accelerate the development and commercialization of our products. These strategic partnerships enhance our capabilities and expand our reach in the global market. Market Presence: Listed on the Main Board of the Hong Kong Stock Exchange since April 2021, Zhaoke Ophthalmology has established a strong market presence and continues to grow its footprint in the ophthalmic pharmaceutical industry. Our experienced marketing team is dedicated to promoting our products and educating healthcare professionals about the benefits of our therapies. Commitment to Innovation: Innovation is at the core of Zhaoke Ophthalmology’s operations. We are committed to advancing the field of ophthalmology through continuous research and development, ensuring that our therapies address the evolving needs of patients and healthcare providers.
Xuxin (HongKong) Biotechnology Co., Limited
Xu Xin (Hong Kong) Biotechnology Co., Ltd. is a high-tech enterprise located in the Hong Kong Science Park, specializing in AI-driven research and development on innovative RNA-targeted therapy. The company is committed to addressing the unmet clinical needs in genetic diseases, neurological disorders, chronic diseases, and other therapeutic areas, and is dedicated to advancing the development of precision medicine through cutting-edge technologies. The company possesses a world-first RNA precision editing technology platform, which includes the world’s largest ADAR substrate editing library, an RNA fragment excising tool, and the AI-driven ATOMIC platform. These breakthrough innovations provide strong support and assurance for the company’s research and development of novel drugs. Through these top-notch technologies, the company is able to overcome the limitations of traditional small-molecule and biologic drugs, and to address key therapeutic challenges such as frameshift mutation diseases, single-point mutation genetic diseases, metabolic diseases and Immuno-oncology diseases. At the same time, our technical strategies ensure to avoid the irreversible off-target safety risks associated with DNA-level gene editing therapies.
XREC INTERNATIONAL LIMITED
XRecer: The Future of All-in-One Music Intelligence 1. About XRecer : Founded by a collective of audio engineers, AI machine learning specialists and music producers, we are here to redefine what’s possible in music creation. we provide the audio industry with innovative, next-generation solutions designed for the modern era 2. The XRecer Story: Where Innovation Meets the Soul of Sound Audio has moved from analog warmth to digital efficiency, yet many of us still find ourselves chasing the authentic feel of the past. Traditional Digital Signal Processing (DSP), relying on static code, has finally reached its limit. XRecer represents a new chapter. We’ve moved beyond simple emulation; our technology doesn’t just “copy” gear—it breathes and reacts to every note with the instinct of an analog circuit. We empower musicians to stop worrying about the tech and focus on what matters most: the music. 3. The XRecer Team: A Global Collective of Expertise We operate as a global collective, drawing expertise from Hong Kong, Mainland China, Singapore, the UK, and the USA. Our team includes the same architects who once built the core technologies for the world’s most iconic audio brands. Backed by 20 years of heritage in high-end audio, we are driven to transcend the boundaries of what’s possible, creating an ecosystem where algorithmic innovation meets seamless hardware-software integration. 4. What Makes XRecer Different? Our Core Foundations Neural Intelligence: The Analog Feel, Restored Digital shouldn’t mean static. We focus on behavior, not just snapshots. By analyzing the non-linear character of vintage gear, we’ve built devices that respond to the nuance of every note. It’s that organic, “breathing” sensation of a live circuit—now available in a digital world that finally feels real. Behind the Sound: 20 Years of Engineering We didn’t just enter the audio industry; we helped build it. For two decades, our team acted as the “silent architects” for global audio leaders. XRecer is the culmination of that journey. Because we own every line of our designs, we can combine that experience with audiophile-grade hardware to build tools that won’t let you down, whether you’re in a high-stakes studio session or live on stage. Seamless Workflow: Focus on Music, Not Menus We’re tired of professional gear that feels like a headache to use. If a tool is intimidating, it’s failing the artist. We took the “it just works” logic of modern smartphones and brought it to the audio world, effectively killing the learning curve with an effortless, human-centric UI/UX. 5. Our Vision: Empowering the Soul of Music At XRecer, we fundamentally believe that technology should adapt to the artist—never the other way around. Our goal is simple: to connect every musician to their instrument, from industry legends to those just starting their journey. XRecer is more than a manufacturer. We strive to be your dedicated partners in music, committed to bringing your creative inspirations to life.
XOXO Beverages Limited
XOXO Beverages Limited is a beverage technology company started by a team of engineers, mixologists, and bar owners. It created Asia’s first award-winning smart beverage dispenser, crafting personalized mixed drinks in 30 seconds.XOXO leverages AI and robotics to deliver personalized, interactive experiences.Driving digital transformation
Xiaomo Biotech Limited
Xiaomo Biotech is an expert on RNA biosynthesis. Our green biomanufacturing technology produces highly potent, specific, and cost-effective siRNAs (to kilograms) for various RNAi applications including gene knockdown in mammalian cells, high-throughput RNAi screen and RNAi pesticide. Xiaomo is committed to developing cutting-edge biotech products based on RNA interference (RNAi), a natural process which uses small interfering RNAs (siRNAs) to silence target genes in a precise manner. Xiaomo possesses a revolutionary RNAi platform technology known as the ‘prokaryotic siRNA’ (pro-siRNA) technology. The pro-siRNA technology uses bacteria as siRNA ‘factory’ instead of using chemical synthesis. This unique biomanufacturing method enables cost-effective and environmentally friendly production of highly effective siRNAs on a massive scale. Xiaomo has the capacity to produce siRNAs in gram to kilogram scales using bacterial fermentation. Xiaomo has also developed a customized high-throughput RNAi screen technique to identify potential therapeutic target genes in a disease, that could lead to the development of novel RNAi therapeutics. Currently, Xiaomo is offering various biomanufactured siRNA and RNAi library products to the R&D market. Xiaomo’s R&D efforts focus on developing first-in-class RNA pesticides for important crop pests including fungi, insects and nematodes. The ultimate goal of Xiaomo is to provide effective and affordable RNAi solutions for improving both human health and agricultural health. Xiaomo Biotech (www.xiaomobio.com) was founded at Hong Kong Science Park in 2019. We have recently established R&D and production sites in Shanghai Zhangjiang and Suzhou Kunshan China.
Xeroptix Technology Limited
Xeroptix Technology Limited specializes in developing AI hardware and AI SaaS platforms, including the Aurora Arc series of smart devices and the Xero-SaaS platform. These solutions enable individuals and enterprises to efficiently train, build, deploy, and scale AI vision applications in real-world scenarios without requiring any coding.
Wuxi Xianglong Medical Material Co., Ltd.
We’re a group of expertise in TPU and TPU laminated film supplied in rolls, operating both in Vietnam and China. We focus on supplying reliable material for medical device applications, regulatory compliant and cost-effective.